Statement Of Cash Flows [Abstract]

ABIONYX Pharma - Filing #831404

Concept As at
2023-12-31
2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Income taxes paid (refund), classified as operating activities
0 EUR
0 EUR
Cash flows from (used in) operating activities
3 698 EUR
3 359 EUR
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities
0 EUR
0 EUR
Purchase of property, plant and equipment, classified as investing activities
104,000 EUR
165,000 EUR
Proceeds from sales of intangible assets, classified as investing activities
0 EUR
0 EUR
Purchase of intangible assets, classified as investing activities
26,000 EUR
10,000 EUR
Cash flows from (used in) investing activities
130,000 EUR
175,000 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
4 178 EUR
0 EUR
Cash flows from (used in) financing activities
3 886 EUR
194,000 EUR
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
58,000 EUR
3 728 EUR
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
0 EUR
0 EUR
Cash and cash equivalents
4 104 EUR
4 046 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.